These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 12560434)

  • 1. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
    Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
    J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
    Gago FE; Fanelli MA; Ciocca DR
    J Steroid Biochem Mol Biol; 2006 Jan; 98(1):36-40. PubMed ID: 16188438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
    Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
    J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II.
    Pritchard KI; Levine MN; Tu D
    J Clin Oncol; 2003 Feb; 21(3):399-400. PubMed ID: 12560425
    [No Abstract]   [Full Text] [Related]  

  • 9. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
    Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer.
    Love RR; Laudico AV; Van Dinh N; Allred DC; Uy GB; Quang le H; Salvador JD; Siguan SS; Mirasol-Lumague MR; Tung ND; Benjaafar N; Navarro NS; Quy TT; De La Peña AS; Dofitas RB; Bisquera OC; Linh ND; To TV; Young GS; Hade EM; Jarjoura D
    J Natl Cancer Inst; 2015 Jun; 107(6):djv064. PubMed ID: 25794890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.